This is a Phase 3, long-term open-label extension study to evaluate the safety, tolerability and efficacy of tofacitinib in subjects with active PsA who have previously participated in randomized studies of tofacitinib for this indication.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01976364?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
